There are currently 981 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
NCT05660382
Recruiting
The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants w... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/23/2024
Locations: Alamo ENT Associates, San Antonio, Texas
Conditions: Otomycosis
Register for Updates
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
NCT03160274
Recruiting
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: University of Texas Health Science Center, San Antonio, Texas
Conditions: Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
Register for Updates
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230
Recruiting
This is an open-label single arm study. All patients will receive the investigational agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas
Conditions: Glioblastoma
Register for Updates
Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline
NCT06556095
Recruiting
Following the removal of a tooth, a bone graft is often placed in the socket to try to maintain the volume of bone that was there when the tooth was present so that the bone does not "shrink". The bone graft is kept in place with a small piece of material over the top of the tooth socket and with stitches. This procedure is called "Ridge Preservation". Many different materials are used for ridge preservation, including bone allografts (bone grafts derived from a human tissue donor). These bone a... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/18/2024
Locations: UT Health Science Center at San Antonio, School of Dentistry, San Antonio, Texas
Conditions: Bone Graft, Tooth Extraction
Register for Updates
VIA Disc NP Registry 3.0
NCT06345690
Recruiting
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Advanced Spine and Pain Center, San Antonio, Texas
Conditions: Discogenic Pain, Back Pain, Back Pain, Low
Register for Updates
Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/29/2024
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Register for Updates
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: START San Antonio, San Antonio, Texas
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Register for Updates
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Local Institution - 0006, San Antonio, Texas +1 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
NCT06246786
Recruiting
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Mays Cancer Center, UT Health San Antonio, San Antonio, Texas
Conditions: Triple Negative Breast Cancer, DNA Damage Repair Deficiency
Register for Updates
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Research Site, San Antonio, Texas
Conditions: B-cell Lymphoma, Non-hodgkin Lymphoma, B-cell Malignancy, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Texas Oncology-San Antonio, San Antonio, Texas
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
NCT05841563
Recruiting
The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - expansion) will be to evaluate the antitumor activity of PM54 in terms of clinical benefit (response or stable disease \[SD\] ≥4 months associated with tumor shrinkage), according to the RECIST v.1.1 (or modified RECIST \[mRECIST\] v.1.1 in case of malignant pleural mesothelioma \[MPM\]) and/or serum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas
Conditions: Advanced Solid Tumor
Register for Updates